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Summary
BACKGROUND: Since the advent of high-throughput se-
quencing technologies, organised germline screening, in-
dependent of the personal and family cancer history, has
been frequently proposed. Since ethnic and geographic
populations significantly differ in their mutation spectra
and prevalence, one critical prerequisite would be the
knowledge of the expected carrier frequencies.
OBJECTIVE: For the first time, in a retrospective non-can-
cer related cohort from a single Swiss genetic centre, we
systematically assessed the prevalence of secondary find-
ings in 19 genes (BRCA1/2 plus 17 non-BRCA genes)
previously designated by the US National Comprehensive
Cancer Network (NCCN) for hereditary breast and ovarian
cancer (HBOC) germline testing.
DESIGN: A total of 400 individuals without a cancer diag-
nosis undergoing whole-exome sequencing (WES) analy-
sis for neurodevelopmental disorders (NDDs) from 2015
to 2017 at IMG Zurich were included after quality assess-
ment. Among these, 180 were unaffected parental cou-
ples, 27 unaffected parental singles and 13 NDD index
patients (mean age 43 years). The majority of the cohort
was of Caucasian ethnicity (n = 336, 84.0%) and of North-
west European ancestry (n = 202, 50.5%), for 70 of whom
(42.5%) an autochthonous Swiss descent was assumed.
For WES filtering of rare, potentially actionable secondary
variants in HBOC genes, an overall minor allele frequency
(MAF) below 0.65% was used as cut-off. Each rare variant
was manually evaluated according to the recommended
ACGM-AMP standards, with some adaptations including
“hypomorphic” as an additional distinct pathogenicity
class.
RESULTS: Overall, 526 rare secondary variants (339 dif-
ferent variants) were encountered, with the BRCA1/2
genes accounting for 27.2% of the total variant yield. If
stratified for variant pathogenicity, for BRCA1/2, three
pathogenic variants were found in three females of Italian
ancestry (carrier frequency of 0.8%). In the non-BRCA
genes, five carriers of (likely) pathogenic variants (1.3%)
were identified, with two Swiss individuals harbouring the
same CHEK2 Arg160Gly variant known to be recurrent
among Caucasians. Hence, the overall carrier rate added
up to 2.0%. Additionally, seven various hypomorphic
HBOC predisposing alleles were detected in 22 individuals
(5.5%).
CONCLUSION: We provide the first evidence of a high
prevalence of HBOC-related cancer susceptibility in the
heterogeneous Swiss general population and relevant
subpopulations, particularly in individuals of Italian de-
scent. These pioneering data may substantiate popula-
tion-based HBOC screening in Switzerland.
Keywords: hereditary breast and ovarian cancer
(HBOC), Swiss, Italian, universal screening, population-
based screening, secondary findings, genetic incidentalo-
ma
Introduction
According to the Swiss Cancer Report 2015 [1], an average
of more than 6200 females are diagnosed with breast or
ovarian cancer in Switzerland per year, with breast cancer
being the leading cancer in women and accounting for a
third of all new cancer cases. It is assumed that approxi-
mately 5–10% of breast cancers and 10–15% of epithelial
ovarian cancers arise in women with an underlying mono-
genic hereditary predisposition, frequently caused by dele-
terious germline variants in the cancer susceptibility genes
BRCA1 and BRCA2 (designated as hereditary breast and
ovarian cancer [HBOC] syndrome) [2]. Assuming an aver-
age prevalence of 5%, ~2000–4000 HBOC index cases are
estimated to be currently living in Switzerland, according
to the CASCADE study proposal for cascade cancer pre-
disposition screening in Switzerland [3].
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However, about one in five Swiss breast cancer patients
are diagnosed when they are younger than 50 years [4, 5],
which may indicate genetic susceptibility and, hence, may
reflect a significant underdiagnosis of underlying germline
alterations. Likewise, only an estimated 20–25% of famil-
ial breast cancer cases are explained by BRCA1/2 patho-
genic variants and >60% of the hereditary predisposition
remains unexplained [6, 7]. Nevertheless, in current prac-
tice, genetic testing is usually limited to the evaluation of
patients meeting strict criteria for an individual or fami-
ly cancer history, as specified by various (inter-)national
guidelines [8–11]. These restrictions of the testing ap-
proach, which are validated for the minimum mutation de-
tection rate of ≥10% as a consensus [11], have been more
and more questioned by recent studies using gene-pan-
el based diagnostic strategies [12–14]. To this end, were
the US National Comprehensive Cancer Network (NCCN)
HBOC susceptibility screening guideline endorsed 17
non-BRCA susceptibility genes, which were found to con-
fer a high to moderate breast and/or ovarian cancer risk,
partially within the context of clinically broader hereditary
cancer syndromes (HCSs), such as Li-Fraumeni, Lynch
and PTEN hamartoma tumour syndromes [8].
Given that HBOC patients are at high risk of cancers at
a younger age and of high grade, routine screening pro-
grammes lack sufficient sensitivity for the detection of
HBOC-associated lesions at early stages. Magnetic reso-
nance imaging screening from an early age and risk-reduc-
ing measures such as chemo-prevention and prophylactic
surgery, however, have been shown to lead to a substan-
tial decrease of HBOC-associated morbidity and mortality
[15, 16]. These preventive strategies, as well as options for
tailored therapies such as poly-ADP-ribose polymerase in-
hibitors (PARPi) pharmacotherapy for BRCA1/2-associat-
ed malignancies [17], mean that diagnostic assessment for
HCSs plays a crucial role in oncological care.
Therefore, since the advent of the high-throughput se-
quencing technologies, organised population-based screen-
ing for BRCA1/2 for populations harbouring a high path-
ogenic variant burden has been proposed several times.
However, knowledge of the expected carrier frequency and
possible recurrent (founder) mutations would be a critical
prerequisite to giving precise estimations about the predic-
tive values and determining if they are at diagnostically
and economically reasonable levels [18–20].
Systematic investigations about specific carrier frequen-
cies in the general – particularly autochthonous – Swiss
population are nevertheless lacking. This paucity of reports
even extends to the mutation frequency and spectrum in
the setting of HBOC-affected cohorts originating from
Switzerland and its different language areas, although
these have been well studied in other, also non-Caucasian,
populations.
This scarcity of studies prompted us to retrospectively as-
sess secondary findings in the 19 NCCN-designated
HBOC-related genes in a Swiss monocentric cohort of
400 individuals, almost half of whom were of assumed
autochthonous Swiss descent, previously undergoing non-
cancer related whole-exome sequencing (WES) analysis.
Since these findings were not related to the initial reason
for referral, but were identified via proactive searching, the
term “secondary findings” was used throughout this study
[21, 22]. Hence, for the first time, we provide data on the
prevalence of HBOC-related genetic alterations in the gen-
eral population in Switzerland, which may provide a first
data basis for specifying carrier rates for genetic coun-
selling or future cancer screening programmes. The pre-
sent study indicated an unexpectedly high carrier frequen-
cy for genetic variants predisposing to HBOC, especially
among the Swiss subpopulation of Italian descent.
Material and methods
Study population
WES data with consent for secondary analyses from 404
subjects enrolled between 2015 and 2017 in our local
monocentric study on genetic causes of neurodevelopmen-
tal disorders (NDDs) were available for this study. As de-
scribed below, the WES datasets of four subjects were
excluded because of insufficient data quality. The study
population therefore consisted of 400 independent individ-
uals (198 males and 202 females; median age 43 years), of
whom 180 (90.0%) were parental couples not affected by
NDDs, 27 (6.8%) parental singles, and 13 (3.3%) NDD in-
dex patients (table 1). For five of these index patients, ge-
netic NDD diagnosis had been established; in eight index
cases, the definitive aetiology remained unclear. For the
latter, hitherto known NDD-associated tumour syndromes
including Fanconi anaemia could be virtually excluded
by initial phenotype-driven and panel-agnostic WES, and
chromosomal microarray analyses (CMA) (Affymetrix
CytoScan® HD or 2.7M arrays) [23, 24]. In none of the in-
vestigated individuals was a personal cancer history docu-
mented; in 28 individuals (7.0%), however, single or multi-
ple relatives of different relationship degrees were reported
to be affected by various cancer entities (supplementary
table S1, appendix 1). The study cohort mostly included
Caucasians (n = 336, 84.0%) of North West European an-
cestry (n = 202, 50.5%), among whom 170 (42.5%) were
assumed to be of autochthonous Swiss descent. Non-Cau-
casians (n = 64, 16.0%) predominantly originated from the
Middle East / North Africa (n = 35; 8.8%). Consanguinity
was noted for 10.0% of individuals with a degree of rela-
tionship ranging from the sixth to the third degree. Genetic
testing was part of a research project approved by the local
ethics committee. Written informed consent for all kinds of
scientific research questions, as well as for publication of
clinical information, was obtained from participants.
Whole-exome sequencing data analysis
WES analyses was performed on DNA extracted from pe-
ripheral blood lymphocytes using Agilent (Santa Clara,
CA, USA) SureSelect XT Clinical Research Kit (v5 or
v6) for capturing, followed by bi-directional paired-end se-
quencing of 125 base pairs (bps) on a HiSeq2500 platform
(Illumina, San Diego, California, USA) and alignment to
the hg19 reference genome using NextGENe software
(Softgenetics, State College, Pennsylvania, USA). Cut-off
values for alternate read fraction and minimum coverage
were 16% of supporting reads and 20× read depth, respec-
tively. WES data with less than 85% of the exome cov-
ered at ≥20× read depth were considered to be of insuffi-
cient quality. Accordingly, WES datasets of four subjects
were excluded from this study in the course of quality
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control. In the remaining 400 WES datasets, on average
95.9% of the WES targeted bases were covered with ≥20×
reads (87.1–98.9%) yielding an average read depth of 232×
(72–635×) (supplementary figure S1, appendix 4). For the
present investigation, the coding regions including 12
flanking intronic base pairs (CDS ±12 bps) of 19 genes
related to HBOC syndrome, namely BRCA1/2 plus 17
non-BRCA genes specified by the NCCN guideline "Ge-
netic/Familial High-Risk Assessment: Breast and Ovarian"
[8] (v.2.2017; see fig. 1B), were evaluated using the
NextGENe software. In our exploratory preliminary analy-
sis of variants with a minor allele frequency (MAF) ≤2%,
the low-risk BRCA2 nonsense allele
NM_000059.3:c.9976A>T was the sequence alteration
showing the highest overall MAF of 0.65% and that still
had evidence of a potential clinical effect. An overall MAF
threshold of ≤0.65% (gnomAD database, v2.0 and later)
was thus set to define rare variants potentially predisposing
to HBOC. In order to ascertain sequence quality and con-
fidence, each variant was visually validated and those con-
sidered true positives all had a NextGENe overall mutation
score above the default quality threshold (≥12). The anno-
tation of the filtered sequence variants was performed us-
ing NextGENE and Alamut Visual software (v.2.10; Inter-
active Biosoftware, Rouen, France) or by manual curation
(table S2, appendices 2A and 2B).
For variant annotation and pathogenicity assessment, the
web resources as detailed at the end of the article were
used.
Variant classification and Sanger sequencing valida-
tion
The clinical relevance of the identified sequence variants
was manually classified according to the current standards
recommended by the American College of Medical Ge-
netics and Genomics and the Association for Molecular
Pathology (ACMG-AMP) [25], with some adaptations.
The variants were evaluated using a five-tier scheme and
categorised as “pathogenic” (P), “likely pathogenic” (LP),
“hypomorphic” (HM), “variant of uncertain significance”
(VUS) and “(likely) benign” (B/LB) with the ACMG-
AMP pathogenicity categories “benign” (B) and “likely
benign” (LB) being subsumed to “(likely) benign” for sim-
plicity, and a novel category “hypomorphic” being intro-
duced. Given the empirical pathogenic variant burden in
the Exome Aggregation Consortium (ExAC) database
[26], the frequency levels “within pathogenic range” (≤8
total alleles in the ExAC database; corresponding to the
moderate ACMG-AMP “PM2” criterion), “somewhat
high” (>8 total alleles), “high” (overall MAF >0.1%), and
“very high” (overall MAF >0.5%) were introduced as pro-
posed by Nykamp et al. [27] for genes with autosomal-
dominant inheritance. Also according to Nykamp et al., the
MAF levels “high” and ”very high” (overall MAF >0.1%)
were considered sufficient criteria for B/LB classification
if there existed no additional corroborating evidence for
variant pathogenicity. Variants were classified as hypomor-
phic if they had been recurrently observed and shown a
low to moderate association with cancer in large case-con-
trol studies, with evidence for functional damaging effects
but controversial assessment in the literature. Of note, the
classification criteria proposed by the ENIGMA consor-
tium for BRCA1/2 variants are solely intended to differen-
tiate germline high-risk BRCA1/2 variants from those with
low or no risk. These guidelines are therefore explicitly not
intended to evaluate and classify non-high-risk variants as-
sociated with an intermediate or moderate risk (ENIGMA
BRCA1/2 Gene Variant Classification Criteria, v2.5.1., 29
June 2017). In the absence of contradictory evidence, vari-
Table 1: Detailed demographic and recruitment data for all enrolled subjects.
Total no. of investigated individuals 400
Median age 43 years
n %
Sex Male 198 49.5
Female 202 50.5
Analysed by WES Parental couples 180/220 (360/400) 81.8 (90.0)
Parental singles 27/220 (27/400) 12.3 (6.8)
NDD index singles* 13/220 (13/400) 5.9 (3.3)
Consanguinity of parental couples 20/180 (40/400) 11.1 (10.0)
Ancestry† Caucasian All 336 84.0
North West European All 202 50.5
Autochthonous Swiss‡ 170 42.5
South European 117 29.3
East European 17 4.3
Non-Caucasian All 64 16.0
Middle Eastern / North African 35 8.8
East Asian 1 0.3
South Asian 20 5.0
Sub-Sahara African 8 2.0
American 7 1.8
NDD = neurodevelopmental delay; WES = whole-exome sequencing * No evidence of a NDD-associated tumour disposition syndrome. Diagnosis had been established for five
index patients (MIM-number of the respective phenotype and the aetiological gene in brackets): ID 65891 (MIM# 300055, MECP2); ID 71642 (MIM# 607313, ROBO3); ID 73869
(MIM# 604804, CDK5RAP2); ID 74275 (MIM# 613382, PTHLH); ID 80540 (MIM# 615656, chromosome 15q11.2 microdeletion syndrome). For eight index patients, the definitive
genetic diagnosis remained unclear (cardinal phenotypic features in brackets): ID 57429 (NDD, myelination defects, hypotonia, hypoplasia of abdominal wall muscles, pectus
excavatum, ataxia/athetosis, dysmorphism); ID 62805 (borderline macrocephaly/macrosomia, speech delay, attention-deficit disorder); ID 66856 (septo-optic dysplasia); ID 68241
(NDD, macrosomy, behavioural problems); ID 68355 (NDD); ID 72678 (NDD, macrocephaly, dissociated cognitive dysfunction, language-acquisition disorder); ID 75672 (recurrent
generalized fever-associated seizures); ID 75676 (language-acquisition disorder, macrocephaly, behavioral problems, learning disorder) † In the case of mixed ancestry, multiple
ancestry labels per individual ‡ Self-reported Swiss descent, with at least one parental side originating from Switzerland
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ant classifications reviewed by international expert consor-
tia [28–32] were used as a stand-alone criterion. Variant in-
terpretations provided in locus-specific databases (LSDBs)
were taken into account for pathogenicity assessment only
if they were reviewed by multiple submitters without in-
terpretation conflicts (”two-star” review status in the NCBI
ClinVar database; corresponding to the supporting ACMG-
AMP “BP6” and “PP5” criteria). For the evaluation of
computational evidence data, a prediction consensus was
built considering seven functional and conservation pre-
diction algorithms (see web resources). To this end, CADD
Phred and GERP_RS scores of ≥20 and >2 were set as
cut-off values for deleteriousness, as suggested elsewhere
[33]. The prediction consensus was assigned as “damag-
ing” (corresponding to the supporting ACMG-AMP “PP3”
criterion) if at least six out of seven prediction algorithms
indicated a deleterious variant effect. Variants for which
1/7 or none of the predictions were damaging were as-
sumed to be neutral and considered to meet the support-
ing ACMG-AMP criterion “BP4”; any other cases were
categorised as “undetermined” (for further details, see leg-
end to table S2 in the appendix). Likewise, potential splice
alterations at the proximal canonical splice site and at in
silico predicted cryptic splice donor/acceptor sites (CSDS/
CSAS) were monitored for all filtered variants by using a
prediction consensus of four different splicing algorithms
(see web resources). A variant was predicted to induce a
potential splicing defect (corresponding to the supporting
ACMG-AMP “PP3” criterion) if at least three algorithms
scored above the relative cut-off values established for the
score differences between wild-type and variant. For these
difference scores, algorithm-specific thresholds were used
as proposed by Tang et al. [34] and Baert et al. [35] and de-
tailed in table S3 (appendix 3).
All variants finally classified as (likely) pathogenic were
confirmed by bi-directional Sanger sequencing on an
ABI3730 capillary sequencer (Applied Biosystems) using
the SequencePilot v.4.4.0 software (JSI medical systems,
Ettenheim, Germany) for evaluation.
Results
Overall, WES data evaluation for the 19 HBOC-related
genes investigated identified 339 different rare variants
(MAF ≤0.65%) with an absolute yield of 526 rare sequence
alterations. With regard to the latter, the BRCA1 and BR-
CA2 genes accounted for 9.3% and 17.9% (combined frac-
tion of 27.2%) of all detected rare variants, respectively
(fig. 1). Among a total of 383 rare non-BRCA variants, in-
cluding 246 different variants, most sequence alterations
affected the ATM (12.2%) and NF1 genes (8.9%), followed
by the CDH1 gene (7.8%). The majority of variants were
missense (59.5%) followed by synonymous (26.8%), non-
coding (9.9%), nonsense (2.5%), and frameshift sequence
variations (1.0%) (table S2, appendix 2).
According to our variant classification, a total of eight sec-
ondary LP/P findings were found (1.5% of all detected
variants), among which three (0.6%) affected BRCA1/2
and five (1.0%) the non-BRCA genes, with the CHEK2
Arg117Gly variant observed in two unrelated individuals.
Figure 1: Distribution and classification of rare variants in HBOC-related genes. (A) Distribution of the secondary variants detected in the 19
NCCN-designated genes related to HBOC with stratification into the BRCA1/2 and non-BRCA genes and the different pathogenicity classes.
In the outer circles, the absolute variant number is given; in the inner circles, the number of the different variants is shown. (B) Detailed patho-
genicity class distribution for each evaluated gene with the absolute variant counts (upper bars) and the number of different variants (lower
bars). For clarity purposes, no difference was made for the pathogenicity classes benign/likely benign and likely pathogenic/pathogenic. B =
benign; HBOC = hereditary breast and ovarian cancer; HM = hypomorphic; LB = likely benign; LP = likely pathogenic; P = pathogenic; VUS =
variant of unclear significance
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Additionally, we detected seven different hypomorphic
variants with the recurrent low-risk BRCA2 c.9976A>T
nonsense allele accounting for one half of all hypomorphic
findings (12/24 HM variant carriers). Furthermore, about
one third of all rare variants were VUSs (155/526, 29.5%),
of which 80.6% (125/155) were detected in the non-BRCA
genes, particularly in ATM, CDH1, and MSH6. The highest
fraction of VUSs relative to the overall gene-specific vari-
ant yield was found for STK11. In contrast, both the TP53
and PTEN genes showed very few sequence variations,
which were all classified as (likely) benign. Among the to-
tal of 155 VUSs, 14.2% (22/155) were novel (previously
unreported in LSDBs and reference populations), whereas
8.4% (13/155) were viewed as a VUS by international
expert panels; an additional 36.8% (57/155) were consis-
tently classified as VUSs by multiple submitters to the
NCBI ClinVar database (“two-star” review status). More-
over, 117 (34.5%) different variants were known to the Hu-
man Gene Mutation Database (HGMD), among which 19
(5.6%) and 90 (26.5%) variants were tagged as “DM” (dis-
ease-causing mutations) and “DM?” (questionable disease-
causing mutations), respectively.
Among the eight LP/P findings, half of the variants were
likely gene-disrupting and half were missense (table 1).
Apart from a novel ATM Glu2156* nonsense variant found
in a 39-year-old Czech female, all variants had been pre-
viously described in the literature and/or LSDBs. For the
BRCA1/2 genes, these included the recurrent high-risk BR-
CA1 c.181T>G European founder allele [36, 37] and two
BRCA2 single nucleotide duplications, both of which are
annotated as pathogenic in the BRCA Exchange or BRCA
Share database. Interestingly, all three BRCA1/2 pathogen-
ic variants were identified in middle-aged females of Ital-
ian ancestry, each of whom had no evidence of personal
or family history of cancer. The non-BRCA-genes included
the recurrent Caucasian CHEK2 c.349A>G
[p.(Arg117Gly)] variant known as a moderate risk allele
for breast cancer [38, 39], which was carried by two unre-
lated subjects originating from the German-speaking part
of Switzerland. As for BRCA1/2, in none of the non-BRCA
mutation carriers any personal and family history of cancer
was reported. Of note, four of these LP/P variants were
transmitted to the index offspring, for all of whom an unre-
lated genetic lesion underlying the particular NDD pheno-
type had been previously elucidated. The genetic consul-
tants of the adult carriers of a LP/P variant were informed
in accordance with the given consent for genetic coun-
selling.
Regarding the HM variants, the recurrent Lys3326* non-
sense variant within the last BRCA2 exon, for which case-
control and genome-wide association studies suggested a
mildly increased risk for HBOC [40, 41] and various other
cancer entities [42], had the highest carrier rate of 2.3%
in our sample (table 2). Of note, two thirds of the carriers
were of autochthonous Swiss descent, which may reflect
a high local prevalence in comparison with the 0.65%
overall MAF. An additional 12 individuals (2.3%) har-
boured six further different HM sequence alterations in the
BRIP1, CHEK2, NBN, and RAD51C genes. Both of the
CHEK2 variants detected [c.320-5T>A, p.(Arg180Cys)]
have been considered as low penetrant breast cancer risk
alleles among white European females [39, 45, 46]. Like-
wise, the RAD51C Gly264Ser variant has been supposed
to confer low ovarian cancer risk elevation [47, 48], which
was corroborated by a partial homology-directed repair de-
ficiency in vivo [49, 50]. For the detected hypomorphic
NBN missense variants [p.(Ile171Val), p.(Arg215Trp)],
minor pleiotropic cancer risks have been suggested by a
meta-analysis conducted by Gao et al. [51]. Table 3 sum-
marises all hypomorphic variants detected.
For the individual variant burden, the carrier prevalence
for at least one rare variant was 28.8 vs 60.8% (BRCA1/2
vs non-BRCA genes) summing up to an overall carrier rate
of 71% (fig. 2). In total, 2.0% of the individuals carried a
LP/P variant (0.8 vs 1.3%); if broken down by sex, in the
202 women of the present cohort, the LP/P variant carri-
er rate was 2.5% (1.5 vs 1.0%). In 5.5% at least one HM
variant was observed. The carrier frequency of at least one
VUS was 32.0% (7.0 vs 27.3%), of which the vast majority
(overall frequency 30.3%) harboured no additional HM or
LP/P variants. Notably, this frequency included two VUS
which were shared by consanguineous parental couples. In
a further third of individuals (33.5%), single or multiple
LB/B variants were found as the only rare sequence alter-
ation.
Most strikingly, when considering the LP/P and HM vari-
ant burden as a whole, 7.3% of the individuals were identi-
fied to be carrier of HBOC-related germline alteration. Of
note, these carrier individuals were not related to each oth-
er. Since none of the 13 NDD index patients exhibited any
LP/P variant, no relevant difference in the carrier percent-
ages existed when the entire study population was com-
pared to the non-index proband group. Likewise, the car-
rier frequency did not significantly change if the analysis
was restricted to the individuals of Swiss descent.
Discussion
Approaches to comprehensive population-wide genetic
screening are being increasingly discussed since the advent
of early high-throughput sequencing technologies. Howev-
er, routine BRCA1/2 assessment for the entire or female
population is currently not recommended [8, 9, 61, 62].
Nevertheless, according to the HBOC guideline by the
Swiss Group for Clinical Cancer Research (SAKK), indi-
viduals of Ashkenazi Jewish heritage should be referred
for genetic testing, irrespective of their personal or family
cancer history [9]. For the expansion to further ethnicities,
as recently proposed by Lasker awardee Mary-Claire King
[61], knowledge about expected carrier frequencies and
possible mutation recurrences among the population of in-
terest is critically required [19].
In contrast to the traditional estimates of BRCA1/2 muta-
tion carrier prevalence, which range from 0.2% to 0.3%
(1:300 to 1:500) in the general female population [62], we
found in our total cohort a significantly higher carrier rate
of 0.8%. However, recent empirical data from the ExAC
database indicate a BRCA1/2 mutation population frequen-
cy of 0.41% in total and of 0.51% in the European pop-
ulation (exclusion of data from The Cancer Genome At-
las [TCGA], considering pathogenic missense mutations
known to the ENIGMA database and all protein-truncating
variants [PTVs] of the respective canonical transcript out-
side the regions distal to the last bona-fide pathogenic
PTV and sequencing error-prone repeats) [63]. This find-
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ing has very recently been confirmed by the Geisinger My-
Code initiative for precision medicine, who reported in
>50,000 mostly Caucasians a prevalence of 1:180 (0.56%)
for Sanger-confirmed BRCA1/2 LP/P variants when con-
trolled for relatedness up to the third degree [64, 65].
Surprisingly, all the three BRCA1/2 carriers in our cohort
were women of Italian descent (South Italy and Sardinia).
When restricted to this subpopulation the carrier rate
would be as extraordinary high as 7.1% (3/42 individuals
of Italian descent), which significantly differs from that
of the non-Italian ancestry subgroup (0/353 with available
Table 2: Summary of all detected (likely) pathogenic variants.
Gene HGVS
cDNA change*
Predicted
AA change
rs num-
ber
dbSNP
147
Function Founder mu-
tation?
Evidence (ACMG
evidence catego-
ry, if meeting)
[25]
Final classifi-
cation
Carrier
ID
Age,
y
Sex Ancestry Variant
transmitted
to index?
NDD diagnosis
established for
affected off-
spring†
BRCA1 c.181T>G p.(Cys
61Gly)
rs2889
7672
Missense Europe [36] Classified as
pathogenic by the
ENIGMA consor-
tium; one of the
most recurrent
founder BRCA1
pathogenic vari-
ants in multiple
European popula-
tions [1]
Pathogenic 67202 36 f South
Italian
N N (NDD, primary
microcephaly,
speech delay,
short stature)
BRCA2 c.4284 dup p.(Gln1429
Serfs*9)
rs8035
9439
Frameshift Greece /
South-East Eu-
rope (?) [43,
44]
Classified as
pathogenic by the
ENIGMA consor-
tium
Pathogenic 47478 44 f South
Italian
(Sicily)
N N (NDD, ataxia,
epilepsy)
BRCA2 c.4719dup p.(Lys
1574*)
None Nonsense n.k. to ENIG-
MA
Predicted LoF-
variant (PVS1);
unreported (PM2);
known to the
UMD Database
with one submis-
sion as causal
(PP5)
Pathogenic 75475 39 f Italian
(Sardinia)
Y Y (MIM
#300243,
SLC9A6)
ATM c.6466G>T p.(Glu2156*) None Nonsense Novel Predicted LoF-
Variant (PVS1);
unreported (PM2)
Likely patho-
genic
67514 39 f Czech N N (NDD, micro-
cephaly, short
stature, hypoto-
nia)
ATM c.6385T>G p.(Tyr2129
Asp)
None Missense Founder effect
n.k.
Mutational hot
spot (PIK-related
kinase/FAT do-
main) (PM1); ab-
sent in population
databases (PM2);
detected in trans
with a second
pathogenic variant
in an A-T patient
(ClinVar submis-
sion
SCV000537715.1,
HUG) (PM3);
highly deleterious
in silico predic-
tions (PP3)
Likely patho-
genic
62542 40 m Turkish
(Kurd)
N Y (MIM
#610536, EF-
TUD2)
BRIP1 c.2684_2687del p.(Ser895*) rs76055
1339
Frameshift Founder effect
n.k.
Predicted LoF-
variant (PVS1);
MAF in population
databases within
pathogenic range
(PM2); known to
HGMD and Clin-
Var databases as
(likely) pathogenic
(PP5).
Likely patho-
genic
68160 55 m Swiss,
German-
speaking
part
Y Y (MTATP6)
CHEK2 c.349A>G p.(Arg117
Gly)
rs2890
9982
Missense Recurrent
among Cau-
casians,but
founder effect
n.k. [38]
Established recur-
rent pathogenic
variant with statis-
tically confirmed
association with
BC [39]
Pathogenic 73281 41 f Swiss,
German-
speaking
part
Y Y (MIM
#121050, FBN2)
CHEK2 c.349A>G p.(Arg117
Gly)
rs2890
9982
Missense 73184 59 m Swiss,
German-
speaking
part
N N (severe NDD,
spastic tetraple-
gia, epileptic en-
cephalopathy)
? = supposed; AA = amino acid; ACMG = American College of Medical Genetics and Genomics; A-T = ataxia telangiectasia; BC = breast cancer; ENIGMA = Evidence-based
Network for the Interpretation of Germline Mutant Alleles; f = female; FAT = FRAP-ATM-TRRAP; HBOC = Hereditary Breast and Ovarian Cancer; HGMD = Human Gene Mutation
Database; HGVS = Human Genome Variation Society; HUG = Hôpitaux Universitaires de Genève; LoF = loss of function; m = male; MAF = minor allele frequency; N = no; NDD
= neurodevelopmental delay; n.k. = not known; PIK = phosphatidylinositol kinase; UMD = Universal Mutation Database; Y = yes * Reference transcripts: BRCA1, NM_007294.3;
BRCA2, NM_000059.3; ATM, NM_000051.3; BRIP1, NM_032043.2; CHEK2, NM_007194.3 † If NDD diagnosis is established, the phenotype MIM number and the aetiological
gene is given; if not, cardinal phenotypic features are summarised
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ancestry information; p = 0.0011, Fisher's exact test). Of
note, neither the BRCA1/2 carriers, nor the carriers of LP/
P variants in non-BRCA genes had a documented personal
or family history of cancer and therefore they are not listed
in table S1.
This unprecedentedly high pathogenic variant rate in BR-
CA1/2 might be explained by the small sample size, but
could reflect an actually higher BRCA1/2 mutation preva-
lence among subjects originating from Italy. In accordance
with the latter assumption, in larger cohorts of Italian pa-
tients with familial breast/ovarian cancer, consistently high
BRCA1/2 carrier rates of up to 33.6% have been reported,
with multiple, partially regionally recurring, founder muta-
tions accounting for more than 10% of all BRCA1/2 path-
ogenic variants [66–69]. In particular, in a large unselected
invasive ovarian cancer series from Ontario, Canada, pa-
tients of Italian origin carried the most BRCA1/2 patho-
genic variants (20/46, 43.5%), owing in part to the recur-
rence of three founder mutations, which caused the authors
to discuss more widespread screening among Italians [70,
71]. In line with this, the significantly higher breast/ovar-
ian cancer incidence in Western Switzerland and Canton
of Ticino (Italian-speaking) compared with the German-
speaking part of Switzerland [1] gives reason to speculate
about a higher BRCA1/2 mutation burden among Italian-
descent individuals. Accordingly, two of the three BRCA1/
2 pathogenic variants observed in our patients are recur-
rently seen in Italian breast/ovarian cancer patients. First,
we found in a healthy woman from Southern Italy the BR-
CA1 c.181T>G [p.(Cys61Gly)] variant, which represents
the second most common pathogenic BRCA1 allele among
Italian BRCA1 families (prevalence of 3.9%) [37]. Never-
theless, this variant ubiquitously recurs in Central Europe
and had been identified on a common Polish and Ashke-
nazi Jewish haplotype, suggesting it is an Eastern Euro-
pean founder mutation [72]. The second recurrent Italian
variant (BRCA2: c.4284dup) was previously reported in a
North-Italian patient with synchronous breast and ovarian
cancer with a frameshift BRCA1 mutation in double het-
erozygosis [73] as well as in two other Italian ovarian can-
cer patients [71, 74].
With regard to the non-BRCA genes, the comparability of
our carrier rate of 1.3% is limited, because, to our knowl-
edge, only screenings including subpanels of the 19 NCCN
HBOC genes have been published so far. Most published
WES screenings were for the detection of secondary find-
ings across the ACMG-designated minimum list of 56, or
nowadays 59, medically actionable genes (ACMG-56/59)
[75, 76], among which nine genes only are shared with the
NCCN gene panel, with important genes such as the ATM,
CHEK2, and PALB2 genes missing. These core genes show
the highest mutation prevalence (2.5, 1.5 and 1.2%) in
a very recent series of >5500 German BRCA1/2-negative
breast cancer index patients [77] and also account for 1.0%
of the LP/P variant yield in the present cohort of indi-
viduals without cancer. Nevertheless, ACMG-56/59-based
studies in predominantly Caucasian cohorts found that the
carrier rates in nine shared HBOC genes ranged from 0.3
Table 3: Summary of all detected hypomorphic variants.
Gene HGVS cD-
NA
change*
Predicted AA
change
rs number
dbSNP 147
Function Selected case-control and functional
studies (OR, Odds ratio [95%CI])
Carrier ID Age, y Sex Ancestry
BRCA2 c.9976A>T p.(Lys3326*) rs11571833 Nonsense 2634 BC kindreds: OR = 1.53 (1.00–2.34)
[40]; 41,081 BCAC BC cases: ORw =
1.28 (1.17–1.40), 14,514 OCAC invasive
OC cases: ORw = 1.26 (1.10–1.43) [41];
43,641 genotyped cancer patients: OR
(small cell lung cancer) = 2.06
(1.35–3.16), OR (squamous cell carcino-
ma of the skin) = 1.69 (1.26–2.26) [42];
minor reduction of HDR activity in [52]
12 indivi-du-
als
among these,
eight Swiss indi-
viduals
BRIP1 c.139C>G p.(Pro47Ala) rs28903098 Missense 1882 glioma cases: OR = 3.83
(1.01–14.5) [53]; initially reported in an in-
dividual with early-onset BC and strong
BC/OC family history [54, 55]; destabilisa-
tion and abolishment of the BRIP1 heli-
case activity in [55, 56]
71230 44 F Dutch?
BRIP1 c.139C>G p.(Pro47Ala) rs28903098 Missense 62926 51 F Swiss
CHEK2 c.320-5T>A p.(?) rs121908700 Noncoding 13,087 ECRIC BC cases: OR = 13.9
(1.89–101) [45]; leaky splicing defect im-
plied by [46]
67184 48 M Swiss
CHEK2 c.320-5T>A p.(?) rs121908700 Noncoding 75475 nk F Italian
CHEK2 c.538C>T p.(Arg180Cys) rs77130927 Missense 34,488 unselected white European BC
patients: OR = 1.34 (1.06–1.70) [39]; in-
termediate DNA damage response in [57]
68159 53 F Dutch
NBN c.511A>G p.(Ile171Val) rs61754966 Missense Meta-analysis of 39,731 cancer cases:
OR = 3.93 (1.68–9.20) [51]; impaired DSB
repair activity and increased chromoso-
mal instability in [58]
77074 44 F Swiss
NBN c.511A>G p.(Ile171Val) rs61754966 Missense 77745 32 F Serbian
NBN c.511A>G p.(Ile171Val) rs61754966 Missense 57429 10 M Croatian
NBN c.643C>T p.(Arg215Trp) rs34767364 Missense Meta-analysis of 39,731 cancer cases:
OR = 1.77 (1.07–2.91) [51]; impaired DSB
repair activity in [59, 60]
66310 38 M Portuguese
RAD51C c.790G>A p.(Gly264Ser) rs147241704 Missense 620 BC cases, 480 BC/OC cases: OR
(BC/OC) = 3.44 (1.51–7.80) [48]; interme-
diate HDR activity [49, 50]
70861 51 F Swiss
RAD51C c.790G>A p.(Gly264Ser) rs147241704 Missense 68968 36 F Armenian/Russ-
ian
RAD51C c.790G>A p.(Gly264Ser) rs147241704 Missense 60577 39 F Swiss
? = supposed; AA = amino acid; BC = breast cancer; BCAC = Breast Cancer Association Consortium (http://bcac.ccge.medschl.cam.ac.uk); CI = confidence interval; DSB =
double-strand DNA break; ECRIC = East Anglia Cancer Registration and Information Centre; F = female; HDR = homology-directed repair; HGVS = Human Genome Variation
Society; OC = ovarian cancer; OCAC = Ovarian Cancer Association Consortium; OR, odds ratio; ORw = OR using weighted logistic regression models * Reference transcripts:
BRCA2, NM_000059.3; BRIP1, NM_032043.2; CHEK2, NM_007194.3; NBN, NM_002485.4; RAD51C, NM_058216.2
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to 2.5% [78–83], with variant classification inconsistencies
and other confounding factors. In a couple of pioneer pa-
pers [23, 84–86], large cohorts were screened for more ex-
panded gene panels, including up to 16 genes [87] out of
the present HBOC panel, but these studies also failed to
consider, particularly, the ATM and CHEK2 core genes.
Thompson et al. [88], however, screened almost 2000 can-
cer-free Australian women for secondary findings in a pan-
el of 18 breast cancer-associated genes covering the
non-BRCA core genes ATM, BRIP1, CDH1, CHEK2,
PALB2 and TP53, which is more suitable for the compar-
ison with the data from our cohort. With regard to the
12 overlapping genes, the resulting prevalence was some-
what lower in their study population (1.8%) as compared
with our cohort (2.0%). This also holds true when com-
parison is made for BRCA1/2 (0.65 vs 0.8% in our co-
hort) and non-BRCA genes (1.1 vs 1.3%). This difference
may be partly explained by the inclusion of cancer-free
women exclusively aged >60 by Thompson et al., which
may result in a partial depletion of highly penetrant mu-
tations in their series (mean age in our cohort 43 years).
Similarly, the prevalence of PTVs in eight non-BRCA core
genes in control datasets derived from ExAC was 1.4%
(27,173 non-Finnish European [NFE] individuals), where-
as it was 0.9%, in the hypernormal FLOSSIES populations
(7325 cancer-free woman of European American ancestry
over 70 years of age) [77]. However, in addition to inter-
study variability in sample size, demographic structure and
inclusion criteria, comparability is further hampered by
considerable methodological inconsistencies in the strin-
gency of variant filtering and pathogenicity assessment to-
gether with technical sequencing setups, and therefore da-
ta quality [31, 80–83]. As an illustration, the BRCA1/2
mutation carrier frequency among the Finnish ExAC co-
hort was considerably lower than that of NFE subpopula-
tion (0.08 vs 0.24%); inter-population differences, howev-
er, may be confounded by the contribution of Ashkenazi
Jewish founder mutations present only in the NFE cohort.
Likewise, there is substantial variability between the
Africans, Latinos, East and South Asians with ExAC fre-
quencies ranging from 0.16% to 0.41% among Africans to
Latinos [63], which may be influenced by limitations in
sample size and the fact that the existing literature is biased
towards Caucasian cohorts. The latter may mean that there
is insufficient evidence to classify missense variants recur-
ring among non-Caucasians as definitely pathogenic [89].
Moreover, Maxwell et al. [63], among others, rightly point-
ed out that true population prevalence might be underesti-
mated in available studies, owing to the lack of consider-
ation of copy number variants (CNVs), which account for
~10% of all BRCA1/2 mutations [90], and the disregard of
uncharacterised but (potentially) pathogenic missense vari-
ants. Even though the present study also did not include
CNVs and structural rearrangements, we assessed the clin-
ical significance of missense variants by extensive manual
curation without any database-driven pre-selection variant
filtering strategy, allowing us to give a more representative
reflection of the true mutation burden. Furthermore, we al-
Figure 2: Carrier frequencies in non-cancer related individuals (n = 400) for at least one rare variant (overall MAF ≤0.65) in the HBOC-genes
(dark brown), stratified to the BRCA1/2 and non-BRCA genes and the different pathogenicity classes (inset). Frequencies for mutually exclu-
sive stratification categories (single count of the "highest" applicable pathogenicity category per individual) are given in the inner circle; the fre-
quencies for non-exclusive categories (multiple categories were counted per individual if applicable) in the outer circle. BRCA1/2- and non-BR-
CA-specific carrier frequencies are determined separately and hence non-additive. The absolute counts are given in brackets. B = benign;
HBOC = hereditary breast and ovarian cancer; HM = hypomorphic; LB = likely benign; LP = likely pathogenic; P = pathogenic; VUS = variant
of unclear significance
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so incorporated into our evaluation hypomorphic variants,
which were found in the considerable percentage of 5.5%
of the studied individuals.
In contrast to many other populations, for Switzerland as
a whole, the pathogenic variant spectrum and prevalence
for the HBOC-related genes even in cancer patients is far
from being established. To our knowledge, hitherto on-
ly three Swiss retrospective series with up to 350 breast/
ovarian cancer patients meeting stringent clinical criteria
have been published, in which typical BRCA1/2 patho-
genic variant carrier rates of about 25% were detected [5,
84, 85]. Notably, these studies solely addressed BRCA1/
2 and, regardless of the heterogeneity and peculiarities of
the Swiss population [86, 91], provided no specific inclu-
sion or stratification criteria related to the ancestry of the
enrolled patients. In our cohort, two unrelated individuals
originating from the German-speaking part of Switzerland
shared the pathogenic CHEK2 Arg117Gly variant, which
is one of the most recurrent non-founder CHEK2 mutations
among Caucasians [38]. To our knowledge, this variant has
not yet been characterised in Swiss individuals. Explorato-
ry examinations on the basis of the trio-WES data argue
against a shared CHEK2 haplotype, though only a limit-
ed number of WES covered single-nucleotide polymorphic
(SNP) sites of the CHEK2 haplotype-constituting SNP en-
sembles provided by Einarsdottir et al. [92] and Kaufman
et al. [93] could be analysed.
In conclusion, our pioneer analyses indicate a substantial
high burden of HBOC-related breast and ovarian cancer
susceptibility in the heterogeneous Swiss general popu-
lation and relevant subpopulations, especially in subjects
of Italian descent. Whereas the LP/P variants found in
2.0% of the studied local population and 7.1% of the Ital-
ian subpopulation would warrant clinical action, the clin-
ical implications of the hypomorphic variants detected in
5.5% of the population are currently not defined. Especial-
ly since all the LP/P variants were detected in individu-
als without personal or family cancer history, our data may
corroborate further considerations about population-based
HBOC screenings in Switzerland, particularly for individ-
uals of Italian ancestry, and may serve as a starting point
for screening in larger cohorts, preferably with genetically
inferred ancestry. Organised screening may contribute de-
cisively to the identification of the many mutation carri-
ers who are presently undiagnosed as a result of the cur-
rent restrictive testing practice and therefore excluded from
referral to special HBOC management programmes at an
early age. Nevertheless, the high rate of VUS detected, es-
pecially in non-BRCA genes, would require strict policies
for non-disclosure of VUS, as well as regular and system-
atic reassessments.
Web resources
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Database of Single Nucleotide Polymorphism (dbSNP),
https://www.ncbi.nlm.nih.gov/SNP
Exome Aggregation Consortium (ExAC) Browser,
http://exac.broadinstite.org
Fabulous Ladies over Seventy (FLOSSIES) Database,
https://whi.color.com
Genome Aggregation Database (gnomAD), http://gno-
mad.broadinstitute.org
NHLBI Exome Sequencing Project (ESP) Exome Variant
Server, http://evs.gs.washington.edu/EVS
1000 Genomes (1000G) Project,
http://www.1000genomes.org
Locus-specific databases (LSDBs):
ARUP BRCA Mutation Database,
http://www.arup.utah.edu/database
BRCA Exchange Database, http://brcaexchange.org
Zhejiang University Center for Genetic and Genomic Med-
icine Database, http://www.genomed.org/lovd2/home.php
Global Variome Shared Leiden Open Variation Database
(LOVD), https://databases.lovd.nl/shared/genes
Human Gene Mutation Database (HGMD),
https://www.hgmd.org
International Agency for Research on Cancer (IARC)
TP53 Database, http://p53.iarc.fr
International Society for Gastrointestinal Hereditary Tu-
mours (InSight) Databases, http://www.insight-data-
base.org/genes
Kathleen Cuningham Foundation Consortium for Research
into Familial Breast Cancer (kConFab) Database,
http://www.kconfab.org
LOVD - Human Mismatch Repair Genes, http://HCI-
LOVD.hci.utah.edu/home.php
Mismatch Repair Genes Variant Database,
http://www.med.mun.ca/mmrvariants
NCBI ClinVar Database, https://www.ncbi.nlm.nih.gov/
clinvar
NHGRI Breast Cancer Information Core (BIC) Database,
https://research.nhgri.nih.gov/bic
Universal Mutation Databases (UMD), http://www.umd.be
In-silico functional prediction algorithms:
Align-Grantham Variation Grantham Deviation (GVGD),
http://agvgd.hci.utah.edu
Combined Annotation Dependent Depletion (CADD)
score, http://cadd.gs.washington.edu/score
EMBL-EBI InterPro (v.67.0), https://www.ebi.ac.uk/inter-
pro
Genomic Evolutionary Rate Profiling (GERP++)_Rejected
Substitution (RS), http://mendel.standford.edu/SidowLab/
downloads/gerp
MutationTaster (MutatTaster), http://www.mutation-
taster.org
Polymorphism Phenotyping (PolyPhen)-2, http://genet-
ics.bwh.harvard.edu/pph2
Sorting Intolerant from Tolerant (SIFT), http://sift.jcvi.org
Universal Mutation Database (UMD) predictor,
http://umd-predictor.eu/
In-silico tools for splicing defect prediction (assessed
by Alamut Visual v.2.10 software):
SpliceSiteFinder (SSF)-like, http://www.interactive-
biosoftware.com
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MaxEntScan (MES), http://genes.mit.edu/burgelab/max-
ent/Xmaxentscan_scoreseq.html
Splice Site Prediction by Neural Network (NNS),
http://www.fruitfly.org/seq_tools/splice.html
Human Splicing Finder (HSF), http://www.umd.be/HSF
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Appendix 1
Table S1: Individuals with documentation of family history
of cancer.
Appendix 2A and 2B
Table S2: Synopsis of all detected secondary variants in-
cluding annotations and criteria for pathogenicity assess-
ment.
Appendix 3
Table S3: Synopsis of the in-silico predictions of potential-
ly splice-affecting variants.
Appendix 4
Figure S1: Box plot of the coverage data of all individual
WES analyses.
Appendix 5
Reference list for the supplementary data appendices.
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Original article Swiss Med Wkly. 2019;149:w20092
Swiss Medical Weekly · PDF of the online version · www.smw.ch
Published under the copyright license “Attribution – Non-Commercial – No Derivatives 4.0”.
No commercial reuse without permission. See http://emh.ch/en/services/permissions.html.
Page 13 of 13
